Objective:To evaluate the incidence of major adverse cardiac events (cardiac death, or acute myocardial infarct, or target vessel revascularization) at one year in “real world” patients.Methods:The EINSTEIN registry is an observational, prospective, single center study that consecutively included 103 patients (152 lesions) treated with the Biomatrix™ stent, a biolimus A9-eluting stent with biodegradable polymer.Results:The mean age was 65.0±12.4 years; male gender represented 83.5% of the patients; and 37.9% of them were diabetic. At one-year, major adverse cardiac events occurred in 11.7% of the patients, including 2.9% of cardiac death, 4.9% of with non ST- segment elevation acute myocardial infarction, and 3.9% of target vessel revascularization. Stent thrombosis occurred in only 1% (1 patient) at one-yearfollow-up.Conclusion:The present Registry suggests that new generation biolimus A9 drug-eluting stents are safe and effective in a “real world”, all-comers patients, showing low rates of major cardiac adverse events on long-term follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.